Organic Active Ingredients TRIZ Cases

Combining EFdA and doravirine uses complementary reverse-transcriptase mechanisms to suppress F227C-mutated HIV and raise the resistance barrier.

This case combines ATP-site anchoring with allosteric interactions in macrocyclic compounds to improve LRRK2 potency and selectivity.

Solvent precipitation creates PDE3/PDE4 inhibitor forms A–C with improved solubility and stability for fixed-dose COPD treatment.

Meta-oriented monomers embed radiopacity in microspheres for embolization imaging without separate contrast agents.

Combining an SGLT-2 inhibitor with an ARB targets blood pressure and glucose while limiting drug interactions in cardiovascular care.

Novel triazole carboxylic acid compounds block LPA1 receptor activation, addressing limited treatments for pulmonary, hepatic, and renal fibrosis.

Three-hydrocarbon-group ammonium lipids help form smaller, stable particles for more efficient nucleic acid delivery to tumors.

Acquired resistance and relapse motivate cyclopropyl-amide compounds that inhibit LSD1 and HDAC together for synergistic cancer growth inhibition.

Specific A1AT dosing before and after hematopoietic cell transplantation targets aGVHD while limiting graft impact from immunosuppression.

Conventional anti-inflammatory treatments may suppress inflammation without treating fibrogenesis; PGAM–CHK1 inhibition modulates glycolytic metabolism.

See how staged contraindication and risk-factor filters qualify subjects for OTC statins before dispensing.

A water-free lipid phase and surfactants address poor intestinal absorption while helping protect peptides and proteins from gastrointestinal instability.

Marine polysaccharide vectors protect anthocyanins from digestive conditions while supporting controlled, fluorescently traceable delivery to the colon.

A pulsed electromagnetic field from a plasma discharge tube sensitizes glioblastoma cells before TMZ, improving efficacy without thermal damage.

Swallowing difficulties call for liquid dosing; hydrocolloids, buffers, and thickeners stabilize metronidazole and baclofen suspensions.

Metal-binding groups coordinate CYP11B2 heme iron to reduce aldosterone synthesis while limiting CYP11B1 inhibition and toxicity.

Specific biaryl structures target DGAT2 to reduce triglyceride synthesis while improving liver selectivity and drug exposure.

Dihydroberberine helps interrupt the Maillard reaction by controlling glucose, scavenging ROS, and reducing MDA and MMP-1 linked to skin aging.

This dairy teat dip pairs iodine with chlorhexidine to address limited efficacy and irritation while extending antimicrobial protection against microorganisms.

This case uses NuRD and CAF-1 complexes to repress DUX4, targeting the mis-expression that drives FSHD muscle weakness.

Mutagenized Bacillus subtilis natto fermentation raises MK-7 output to 200–300 mg/L in 16–24 hours while avoiding chemical synthesis.

A 2-oxapregnane compound targets urination disorders regardless of prostate enlargement, supporting effective prolonged treatment.

A specific E4/DRSP formulation maintains contraceptive efficacy while reducing QT prolongation, C-reactive protein elevation, and free testosterone loss.

For diabetic cataract, midodrine targets aldose reductase and hexokinase pathways to preserve lens transparency and support accurate fundus exams.

Dose-adjusted ubrogepant regimens address migraine treatment when hepatic or renal impairment raises accumulation and adverse-effect risks.

BRD4 inhibitors use an acylaminopyrrolo-pyridone core and varied substituents to improve bromodomain selectivity and ADME properties.

Compound A uses an optimized indole structure and ITK inhibition to prolong remission and suppress multiple sclerosis recurrence and progression.

Plinabulin supports neutrophil survival during docetaxel treatment, reducing neutropenia while preserving chemotherapy effectiveness.

Phase-based oral palovarotene dosing uses lower quiescent-period maintenance and higher flare-up dosing to reduce heterotopic ossification.

See how lipophilic cationic moieties linked to antioxidants accumulate in mitochondria to scavenge ROS and address oxidative stress.

Selective sensitivity of leukemia and myeloma cells to WNK1 inhibitors supports cancer targeting while limiting effects on normal cells.

Antioxidants stabilize sodium picosulfate in a ready-to-use liquid with magnesium citrate, supporting complete dosing without stirring.

Genetic markers, plasma sST2 levels, and polygenic scoring support earlier Alzheimer’s risk assessment before symptoms advance.

This case uses varied compound structures and cleavable prodrug forms to inhibit androgen- and estrogen-receptor-dependent proliferation.

Ataluren promotes ribosomal readthrough in children aged 2–5 to restore dystrophin and delay nmDMD progression.

Macrocyclic compounds recruit CypA to block RAF binding to RAS(ON), extending inhibition beyond KRASG12C to other RAS mutants.

Mitochondrial compounds quench ROS, preserve membrane potential, and increase frataxin levels to support cytoprotection in mitochondrial disorders.

TRPV6-binding peptides pair cancer-cell recognition with fluorescent labels or therapeutic agents for targeted detection and delivery.

Formula I compounds selectively inhibit PRMT5 to regulate histone methylation, reverse gene silencing, and support gamma-globin reactivation.

Variable LNP size and encapsulation can undermine potency; controlled lipid-to-nucleic-acid mixing and pH adjustment target more consistent manufacturing.

Limited oral absorption challenges αvβ6 therapy; these small molecules tune structure to combine target potency with permeability.

C-20 oxime ester modification improves aqueous solubility, enabling rapid intramuscular delivery while supporting stable progesterone release.

Altering the MuSK Ig3 domain can reduce BMP interaction and increase neurogenesis for potential neurodegeneration treatment.

Conventional hydrogels can break in load-bearing joints; functionalized HA and telechelic crosslinkers add elasticity for controlled drug release.

A CD44–Notch–HIF-3α4 fusion gene combines three cancer-suppressive functions in one nucleic acid for viral-vector delivery.

JPH203 selectively inhibits LAT1 over LAT2 to target tumor cells while limiting effects on normal cells in cancer therapy.

Crushing and extraction risks are addressed with polymer-matrix tablets compressed above 40 MPa to keep porosity below 10%.

Substituted piperazine compounds activate or partially activate MC4R orally to suppress food intake and limit cardiovascular side effects.

Proteomic profiling of blood-derived samples classifies patients by predicted TIL benefit, improving selection for personalized cancer treatment.

By depleting glutathione and raising ROS, APR-246 induces ferroptosis in NOTCH1-driven T-ALL despite TP53 status.